Caseware UK (AP4) 2023.0.135 2023.0.135 Dublin 2 13 - 18 City Quay Dublin 2 The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 101 'Reduced Disclosure Framework' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 101 'Reduced Disclosure Framework' and the Companies Act 2006. The preparation of financial statements in compliance with FRS 101 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies (see note 3). The following principal accounting policies have been applied: 2.2 Financial reporting standard 101 - reduced disclosure exemptions The company has taken advantage of the following disclosure exemptions under FRS 101: the requirements of paragraphs 45(b) and 46-52 of IFRS 2 Share based payment the requirements of paragraphs 62, B64(d), B64(e), B64(g), B64(h), B64(j) to B64(m), B64(n)(ii), B64(o)(ii), B64(p), B64(q)(ii), B66 and B67 of IFRS 3 Business Combinations the requirements of paragraph 33(c) of IFRS 5 Non Current Assets Held For Sale and Discontinued Operations the requirements of IFRS 7 Financial Instruments: Disclosures the requirements of paragraphs 91-99 of IFRS 13 Fair Value Measurement the requirement in paragraph 38 of IAS 1 'Presentation of Financial Statements' to present comparative information in respect of: - paragraph 79(a)(iv) of IAS 1; - paragraph 73(e) of IAS 16 Property, Plant and Equipment; - paragraph 118(e) of IAS 38 Intangible Assets; - paragraphs 76 and 79(d) of IAS 40 Investment Property; and - paragraph 50 of IAS 41 Agriculture the requirements of paragraphs 10(d), 10(f), 16, 38A, 38B, 38C, 38D, 40A, 40B, 40C, 40D, 111 and 134-136 of IAS 1 Presentation of Financial Statements the requirements of IAS 7 Statement of Cash Flows the requirements of paragraphs 30 and 31 of IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors the requirements of paragraph 17 and 18A of IAS 24 Related Party Disclosures the requirements in IAS 24 Related Party Disclosures to disclose related party transactions entered into between two or more members of a group, provided that any subsidiary which is a party to the transaction is wholly owned by such a member the requirements of paragraphs 130(f)(ii), 130(f)(iii), 134(d)-134(f) and 135(c)-135(e) of IAS 36 Impairment of Assets. The smallest consolidated financial statements presented are that of Clanwilliam Investments (U.K.) Limited at 31 December 2024, in which equivalent consolidated disclosures can be found. These financial statements are available from the Companies Registration Office, Bloom House, Gloucester Place Lower, Dublin 2. New standards adopted as at 1 January 2024 Some accounting pronouncements which have become effective from 1 January 2024 and have therefore been adopted do not have a significant impact on the Company’s financial results or position. Lease liability in Sale and Leaseback (Amendments to IFRS 16 Leases) Classification of liabilities as Current or Non-Current Liabilities with Covenants (Amendments to IAS 1 Presentation of Financial Statements) Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures - Supplier Finance Arrangements For impairment assessment purposes, assets are grouped at the lowest levels for which there are largely independent cash inflows (cash-generating units). As a result, some assets are tested individually for impairment and some are tested at cash-generating unit level. Tangible fixed assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. 2.7 Impairment testing of tangible fixed assets (continued) An impairment loss is recognised for the amount by which the asset's or cash-generating unit's carrying amount exceeds its recoverable amount, which is the higher of fair value less costs of disposal and value-in-use. To determine the value-in-use, management estimates expected future cash flows from each cash-generating unit and determines a suitable interest rate in order to calculate the present value of those cash flows. The data used for impairment testing procedures are directly linked to the Company's latest approved budget, adjusted as necessary to exclude the effects of future reorganisations and asset enhancements. Discount factors are determined individually for each cash-generating unit and reflect management’s assessment of respective risk profiles, such as market and asset-specific risks factors. The assets are subsequently reassessed for indications that an impairment loss previously recognised may no longer exist. An impairment loss is reversed if the asset’s or cash-generating unit’s recoverable amount exceeds its carrying amount. Assets that are subject to depreciation or amortisation are assessed at each reporting date to determine whether there is any indication that the assets are impaired. Where there is any indication that an asset may be impaired, the carrying value of the asset (or cash-generating unit to which the asset has been allocated) is tested for impairment. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's (or CGU's) fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (CGUs). Non-financial assets that have been previously impaired are reviewed at each reporting date to assess whether there is any indication that the impairment losses recognised in prior periods may no longer exist or may have decreased.true true true true true true true true true true true true true true true 2024-01-01 true false false 24 22 03020555 2024-01-01 2024-12-31 03020555 2023-01-01 2023-12-31 03020555 2024-12-31 03020555 2023-12-31 03020555 2023-01-01 03020555 1 2024-01-01 2024-12-31 03020555 1 2023-01-01 2023-12-31 03020555 2 2024-01-01 2024-12-31 03020555 2 2023-01-01 2023-12-31 03020555 3 2024-01-01 2024-12-31 03020555 3 2023-01-01 2023-12-31 03020555 1 2024-01-01 2024-12-31 03020555 e:CompanySecretary1 2024-01-01 2024-12-31 03020555 e:Director1 2024-01-01 2024-12-31 03020555 e:Director5 2024-01-01 2024-12-31 03020555 e:Director6 2024-01-01 2024-12-31 03020555 e:RegisteredOffice 2024-01-01 2024-12-31 03020555 e:Agent1 2024-01-01 2024-12-31 03020555 d:FurnitureFittings 2024-12-31 03020555 d:FurnitureFittings 2023-12-31 03020555 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 03020555 d:OtherPropertyPlantEquipment 2024-12-31 03020555 d:OtherPropertyPlantEquipment 2023-12-31 03020555 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 03020555 d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 03020555 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-01-01 2024-12-31 03020555 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-12-31 03020555 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-12-31 03020555 d:IntangibleAssetsOtherThanGoodwill 2024-12-31 03020555 d:IntangibleAssetsOtherThanGoodwill 2023-12-31 03020555 d:CurrentFinancialInstruments 2024-12-31 03020555 d:CurrentFinancialInstruments 2023-12-31 03020555 d:CurrentFinancialInstruments 4 2024-12-31 03020555 d:CurrentFinancialInstruments 4 2023-12-31 03020555 d:Non-currentFinancialInstruments 2024-01-01 2024-12-31 03020555 d:Non-currentFinancialInstruments 3 2024-12-31 03020555 d:Non-currentFinancialInstruments 3 2023-12-31 03020555 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 03020555 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 03020555 d:Non-currentFinancialInstruments d:AfterOneYear 2024-12-31 03020555 d:Non-currentFinancialInstruments d:AfterOneYear 2023-12-31 03020555 d:ReportableOperatingSegment1 2024-01-01 2024-12-31 03020555 d:ReportableOperatingSegment1 2023-01-01 2023-12-31 03020555 d:UKTax 2024-01-01 2024-12-31 03020555 d:UKTax 2023-01-01 2023-12-31 03020555 d:ShareCapital 2024-12-31 03020555 d:ShareCapital 2023-12-31 03020555 d:ShareCapital 2023-01-01 03020555 d:OtherMiscellaneousReserve 2024-01-01 2024-12-31 03020555 d:OtherMiscellaneousReserve 2024-12-31 03020555 d:OtherMiscellaneousReserve 2023-12-31 03020555 d:OtherMiscellaneousReserve 2023-01-01 03020555 d:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 03020555 d:RetainedEarningsAccumulatedLosses 2024-12-31 03020555 d:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 03020555 d:RetainedEarningsAccumulatedLosses 2023-12-31 03020555 d:RetainedEarningsAccumulatedLosses 2023-01-01 03020555 e:OrdinaryShareClass1 2024-01-01 2024-12-31 03020555 e:FRS101 2024-01-01 2024-12-31 03020555 e:Audited 2024-01-01 2024-12-31 03020555 e:FullAccounts 2024-01-01 2024-12-31 03020555 e:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 03020555 d:OtherDeferredTax 2024-12-31 03020555 d:OtherDeferredTax 2023-12-31 03020555 d:FinancialInstrumentsFairValueThroughProfitOrLoss 2024-01-01 2024-12-31 03020555 d:FinancialAssetsAmortisedCost 2024-01-01 2024-12-31 03020555 d:FinancialLiabilitiesAmortisedCost 2024-01-01 2024-12-31 03020555 d:DevelopmentCostsCapitalisedDevelopmentExpenditure d:InternallyGeneratedIntangibleAssets 2024-01-01 2024-12-31 03020555 2 2024-01-01 2024-12-31 03020555 d:CurrentFinancialInstruments 6 2024-12-31 03020555 d:CurrentFinancialInstruments 6 2023-12-31 03020555 d:CurrentFinancialInstruments 7 2024-12-31 03020555 d:CurrentFinancialInstruments 7 2023-12-31 03020555 d:FinanceLeases d:WithinOneYear 2024-12-31 03020555 d:FinanceLeases d:WithinOneYear 2023-12-31 03020555 d:FinanceLeases d:BetweenOneFiveYears 2024-12-31 03020555 d:FinanceLeases d:BetweenOneFiveYears 2023-12-31 03020555 d:FinanceLeases 2024-12-31 03020555 d:FinanceLeases 2023-12-31 03020555 f:PoundSterling 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure

Financial Statements Clanwilliam Health (DGL) Limited For the year ended 31 December 2024 Registered number: 03020555
Clanwilliam Health (DGL) Limited
Company Information
Directors | Howard John Beggs
| Eileen Byrne
| Stuart Van Rooyen
Company secretary | Erin Lane
Registered number | 03020555
Registered office | Eastcastle House
| 27/28 Eastcastle Street
| London
| W1W 8DH
Independent auditor | Grant Thornton
| Chartered Accountants & Statutory Auditors
| 13 - 18 City Quay
| Dublin 2
Bankers | Citibank N.A. London
| Canada SQ Service CTR
| Citigroup CTR 25
| London
| United Kingdom
| E14 5LB
Clanwilliam Health (DGL) Limited
Contents
| Page
Directors' report | 1 - 2
Directors' responsibilities statement | 3
Independent auditor's report | 4 - 7
Statement of comprehensive income | 8
Statement of financial position | 9
Statement of changes in equity | 10
Notes to the financial statements | 11 - 26
Clanwilliam Health (DGL) Limited
Directors' report For the year ended 31 December 2024 The directors present their report and the financial statements for the year ended 31 December 2024.
Principal activity
The principal activities of the Company is a computer system for private medical consultants that provides a complete practice management software solution.
Results and dividends
The profit for the year, after taxation, amounted to £1,487,330 (2023: £1,365,331). The directors have paid a dividend of £Nil (2023: £500,000).
Directors
The directors who served during the year were:
Howard John Beggs
Eileen Byrne
Stuart Van Rooyen
Future developments
The Company plans to continue its present activities.
Research and development activities
The Company has written off capitalized costs amounting to £257,317 during the year (2023: £Nil) as the expenditure was deemed not financially feasible.
Statement on relevant audit information
Each of the persons who are directors at the time when this Directors' report is approved has confirmed that: ∙so far as the directors are aware, there is no relevant audit information of which the Company's auditor is unaware, and ∙the directors have taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.
Post balance sheet events
On 21 February 2025, the shareholder of the Group agreed to sell 100% of the shares in the Company to Tribe Bidco Limited, a special purpose vehicle incorporated by TA Associates. There are no other subsequent events that will require adjustment or disclosure in the Company’s financial statements.
Auditor
The auditor, Grant Thornton, will continue in office in accordance with section 485 of the Companies Act 2006. Page 1
Clanwilliam Health (DGL) Limited
Directors' report (continued) For the year ended 31 December 2024
Small companies note
In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006. This report was approved by the board and signed on its behalf.
Howard John Beggs Director
Date: 11 July 2025
Page 2
Clanwilliam Health (DGL) Limited
Directors' responsibilities statement For the year ended 31 December 2024 The directors are responsible for preparing the Directors' report and the financial statements in accordance with applicable law and regulations. Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 101 ‘Reduced Disclosure Framework’. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the directors are required to: ∙select suitable accounting policies and then apply them consistently; ∙make judgements and accounting estimates that are reasonable and prudent; ∙state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; ∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business. The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. On behalf of the board Howard John Beggs Director Date: Page 3
Independent auditor's report to the members of Clanwilliam Health (DGL) Limited
Opinion
We have audited the financial statements of Clanwilliam Health (DGL) Limited, which comprise the Statement of comprehensive income, the Statement of financial position, the Statement of changes in equity for the year ended 31 December 2024, and the related notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in the preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 101 ‘Reduced Disclosure Framework’. In our opinion, Clanwilliam Health (DGL) Limited's financial statements: ∙give a true and fair view in accordance with United Kingdom Generally Accepted Accounting Practice of the assets, liabilities and financial position of the Company as at 31 December 2024 and of its financial performance for the year then ended; and ∙have been prepared in accordance with the requirements of the Companies Act 2006.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) ('ISAs (UK)') and applicable law. Our responsibilities under those standards are further described in the 'Responsibilities of the auditor for the audit of the financial statements' section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, namely the FRC's Ethical Standard and the ethical pronouncements established by Chartered Accountants Ireland, applied as determined to be appropriate in the circumstances of the entity. We have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue. Our responsibilities, and the responsibilities of the directors, with respect to going concern are described in the relevant sections of this report. Page 4
Independent auditor's report to the members of Clanwilliam Health (DGL) Limited (continued)
Other information
Other information comprises the information included in the annual report, other than the financial statements and our Auditor's report thereon, including the Directors' report . The directors are responsible for the other information. Our opinion on the financial statements does not cover the information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies in the financial statements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. Opinions on other matters prescribed by the Companies Act 2006 In our opinion, based on the work undertaken in the course of the audit: ∙the information given in the Directors' report for the year for which the financial statements are prepared is consistent with the financial statements, and ∙the Directors' report has been prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment we have obtained in the course of the audit, we have not identified material misstatements in the Directors' report . We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion: ∙adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or ∙the financial statements are not in agreement with the accounting records and returns; or ∙certain disclosures of directors' remuneration specified by law are not made; or ∙we have not received all the information and explanations we require for our audit; or ∙the directors were not entitled to take advantage of the small companies' exemptions from the requirement to prepare a strategic report or in preparing the Directors' report. Page 5
Independent auditor's report to the members of Clanwilliam Health (DGL) Limited (continued)
Responsibilities of management and those charged with governance for the financial statements
Management is responsible for the preparation of the financial statements which give a true and fair view in accordance with United Kingdom Generally Accepted Accounting Practice, including FRS101 and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those charged with governance are responsible for overseeing the Company's financial reporting process.
Responsibilities of the auditor for the audit of the financial statements
The objectives of an auditor are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes their opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. A further description of an auditor's responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report. Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. Owing to the inherent limitations of an audit, there is an unavoidable risk that material misstatement in the financial statements may not be detected, even though the audit is properly planned and performed in accordance with ISAs (UK). The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below: Based on our understanding of the Company and industry, we identified that the principal risks of non-compliance with laws and regulations related to compliance with data protection and Employment laws, Health and Safety Regulation and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulation that have a direct impact on the preparation of the financial statements such as Companies Act 2006 and UK tax legislation. We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to posting inappropriate journal entries to manipulate financial performance and management bias through judgements and assumptions in significant accounting estimates, in particular in relation to significant one-off or unusual transactions. We apply professional scepticism through the audit to consider potential deliberate omission or concealment of significant transactions, or incomplete/inaccurate disclosures in the financial statements. Page 6
Independent auditor's report to the members of Clanwilliam Health (DGL) Limited (continued) Responsibilities of the auditor for the audit of the financial statements (continued) Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud (continued) In response to these principal risks, our audit procedures included but were not limited to: ∙inquiries of management and board on the policies and procedures in place regarding compliance with laws and regulations, including consideration of known or suspected instances of non-compliance and whether they have knowledge of any actual, suspected or alleged fraud; ∙inspection of the Company’s regulatory and legal correspondence and review of minutes of board meetings during the year to corroborate inquiries made; ∙gaining an understanding of the internal controls established to mitigate risk related to fraud; ∙discussion amongst the engagement team in relation to the identified laws and regulations and regarding the risk of fraud, and remaining alert to any indications of non-compliance or opportunities for fraudulent manipulation of financial statements throughout the audit; ∙identifying and testing journal entries to address the risk of inappropriate journals and management override of controls; ∙designing audit procedures to incorporate unpredictability around the nature, timing or extent of our testing; ∙challenging assumptions and judgements made by management in their significant accounting estimates, including useful lives of depreciable assets and provision for expected credit losses of trade receivables; and ∙review of the financial statements disclosures to underlying supporting documentation and inquiries of management. The primary responsibility for the prevention and detection of irregularities including fraud rests with those charged with governance and management. As with any audit, there remains a risk of non-detection or irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations or override of internal control
The purpose of our audit work and to whom we owe our responsibilities
This report is made solely to the Company’s members, as a body, in accordance with chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed. Tracey Sullivan (Senior statutory auditor) for and on behalf of Grant Thornton Chartered Accountants & Statutory Auditors 13 - 18 City Quay Dublin 2 Date: 16 July 2025 Page 7
Clanwilliam Health (DGL) Limited
Statement of comprehensive income For the year ended 31 December 2024
| 2024 | 2023
Note | £ | £
Turnover | 4 | 4,822,623 | 4,709,386
Cost of sales |  | (1,653,533) | (1,698,472)
Gross profit |  | 3,169,090 | 3,010,914
Administrative expenses |  | (2,015,560) | (1,684,156)
Operating profit | 5 | 1,153,530 | 1,326,758
Interest receivable and similar income |  | 418,455 | 123,666
Interest payable and expenses | 7 | (1,768) | (4,131)
Profit before tax |  | 1,570,217 | 1,446,293
Tax on profit | 8 | (82,887) | (80,962)
Profit for the year |  | 1,487,330 | 1,365,331
All amounts relate to continuing operations. There was no other comprehensive income for 2024 (2023: £Nil).
The notes on pages 11 to 26 form part of these financial statements.
Page 8
Clanwilliam Health (DGL) Limited Registered number:03020555
Statement of financial position As at 31 December 2024
|  | 2024 |  | 2023
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Intangible assets | 9 |  | - |  | 222,336
Tangible fixed assets | 10 |  | 13,081 |  | 50,422
Current assets |  |  |  |  |
Debtors: amounts falling due within one year | 11 | 9,418,216 |  | 7,836,926 |
Cash at bank | 12 | 429,207 |  | 398,524 |
|  | 9,847,423 |  | 8,235,450 |
Current liabilities |  |  |  |  |
Creditors: amounts falling due within one year | 13 | (1,095,783) |  | (1,196,035) |
Net current assets |  |  | 8,751,640 |  | 7,039,415
Total assets less current liabilities |  |  | 8,764,721 |  | 7,312,173
Creditors: amounts falling due after more than one year | 14 |  | - |  | (4,336)
Deferred taxation | 15 |  | - |  | (30,446)
Net assets |  |  | 8,764,721 |  | 7,277,391
Capital and reserves |  |  |  |  |
Called up share capital | 16 |  | 2 |  | 2
Other reserves | 17 |  | 141,434 |  | 141,434
Profit and loss account | 17 |  | 8,623,285 |  | 7,135,955
Shareholders' funds |  |  | 8,764,721 |  | 7,277,391
The Company's financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
Howard John Beggs
Director
Date: 11 July 2025
The notes on pages 11 to 26 form part of these financial statements. Page 9
Clanwilliam Health (DGL) Limited
Statement of changes in equity For the year ended 31 December 2024
| Called up share capital | Other reserves | Profit and loss account | Total equity
| £ | £ | £ | £
At 1 January 2024 | 2 | 141,434 | 7,135,955 | 7,277,391
Profit for the year | - | - | 1,487,330 | 1,487,330
At 31 December 2024 | 2 | 141,434 | 8,623,285 | 8,764,721
Statement of changes in equity For the year ended 31 December 2023
| Called up share capital | Other reserves | Profit and loss account | Total equity
| £ | £ | £ | £
At 1 January 2023 | 2 | 141,434 | 6,270,624 | 6,412,060
Profit for the year | - | - | 1,365,331 | 1,365,331
Dividends: Equity capital | - | - | (500,000) | (500,000)
At 31 December 2023 | 2 | 141,434 | 7,135,955 | 7,277,391
| The notes on pages 11 to 26 form part of these financial statements.
Page 10
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024
1. | General information
Clanwilliam Health (DGL) Limited is a private Company limited by shares which is registered and incorporated in the United Kingdom. The Company's registered office is Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH. The principal activities of the Company include the design of computer software for health professionals, mainly general practitioners and private medical consultants, together with the hosting, supply and support of computer systems for the healthcare profession. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 101 'Reduced Disclosure Framework' and the Companies Act 2006. The preparation of financial statements in compliance with FRS 101 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies (see note 3). The following principal accounting policies have been applied:
| 2.2 | Financial reporting standard 101 - reduced disclosure exemptions
The company has taken advantage of the following disclosure exemptions under FRS 101: ∙the requirements of paragraphs 45(b) and 46-52 of IFRS 2 Share based payment ∙the requirements of paragraphs 62, B64(d), B64(e), B64(g), B64(h), B64(j) to B64(m), B64(n)(ii), B64(o)(ii), B64(p), B64(q)(ii), B66 and B67 of IFRS 3 Business Combinations ∙the requirements of paragraph 33(c) of IFRS 5 Non Current Assets Held For Sale and Discontinued Operations ∙the requirements of IFRS 7 Financial Instruments: Disclosures ∙the requirements of paragraphs 91-99 of IFRS 13 Fair Value Measurement ∙the requirement in paragraph 38 of IAS 1 'Presentation of Financial Statements' to present comparative information in respect of: - paragraph 79(a)(iv) of IAS 1; - paragraph 73(e) of IAS 16 Property, Plant and Equipment; - paragraph 118(e) of IAS 38 Intangible Assets; - paragraphs 76 and 79(d) of IAS 40 Investment Property; and - paragraph 50 of IAS 41 Agriculture ∙the requirements of paragraphs 10(d), 10(f), 16, 38A, 38B, 38C, 38D, 40A, 40B, 40C, 40D, 111 and 134-136 of IAS 1 Presentation of Financial Statements ∙the requirements of IAS 7 Statement of Cash Flows ∙the requirements of paragraphs 30 and 31 of IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors ∙the requirements of paragraph 17 and 18A of IAS 24 Related Party Disclosures ∙the requirements in IAS 24 Related Party Disclosures to disclose related party transactions entered into between two or more members of a group, provided that any subsidiary which is a party to the transaction is wholly owned by such a member ∙the requirements of paragraphs 130(f)(ii), 130(f)(iii), 134(d)-134(f) and 135(c)-135(e) of IAS 36 Impairment of Assets. Page 11
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024 2.Accounting policies (continued)
| 2.2 | Financial reporting standard 101 - reduced disclosure exemptions (continued)
The smallest consolidated financial statements presented are that of Clanwilliam Investments (U.K.) Limited at 31 December 2024, in which equivalent consolidated disclosures can be found. These financial statements are available from the Companies Registration Office, Bloom House, Gloucester Place Lower, Dublin 2.
| 2.3 | Impact of new international reporting standards, amendments and interpretations
New standards adopted as at 1 January 2024 Some accounting pronouncements which have become effective from 1 January 2024 and have therefore been adopted do not have a significant impact on the Company’s financial results or position. −Lease liability in Sale and Leaseback (Amendments to IFRS 16 Leases) −Classification of liabilities as Current or Non-Current Liabilities with Covenants (Amendments to IAS 1 Presentation of Financial Statements) −Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures - Supplier Finance Arrangements
| 2.4 | Revenue
Revenue arises mainly from the design and manufacture of computer software for healthcare professionals, mainly pharmacists, private medical consultants and general practitioners, together with the hosting, supply and support of computer systems for the healthcare profession. To determine whether to recognise revenue, the Company follows a 5-step process: 1.Identifying the contract with a customer 2.Identifying the performance obligations 3.Determining the transaction price 4.Allocating the transaction price to the performance obligations 5.Recognising revenue when/as performance obligation(s) are satisfied. Revenue is recognised either at a point in time or over time, when (or as) the Company satisfies performance obligations by transferring the promised goods or services to its customers. The Company recognises contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the statement of financial position. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognises either a contract asset or a receivable in its statement of financial position, depending on whether something other than the passage of time is required before the consideration is due. Contracts with multiple performance obligations Many of the Company's contracts comprise a variety of performance obligations including, but not limited to, hardware, software, elements of design and customisation, after-sales services, and installation. Under IFRS 15, the Company must evaluate the separability of the promised goods or services based on whether they are ‘distinct’. A promised good or service is ‘distinct’ if both: ∙the customer benefits form the item either on its own or together with other readily available resources, and ∙it is ‘separately identifiable’ (i.e. the Company does not provide a significant service integrating, modifying or customising it). Page 12
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024 2.Accounting policies (continued)
| 2.5 | Intangible assets
Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight line basis over their useful economic lives. If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.
| 2.6 | Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. The estimated useful lives range as follows:
|  |  |  | Leasehold improvements | - | Over the life of the lease
|  |  |  | Fixtures and fittings | - | Over 5-8 years
|  |  |  | Right-of-use assets | - | Over 5 years
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
| 2.7 | Impairment testing of tangible fixed assets
For impairment assessment purposes, assets are grouped at the lowest levels for which there are largely independent cash inflows (cash-generating units). As a result, some assets are tested individually for impairment and some are tested at cash-generating unit level. Tangible fixed assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Page 13
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024 2.Accounting policies (continued) 2.7 Impairment testing of tangible fixed assets (continued) An impairment loss is recognised for the amount by which the asset's or cash-generating unit's carrying amount exceeds its recoverable amount, which is the higher of fair value less costs of disposal and value-in-use. To determine the value-in-use, management estimates expected future cash flows from each cash-generating unit and determines a suitable interest rate in order to calculate the present value of those cash flows. The data used for impairment testing procedures are directly linked to the Company's latest approved budget, adjusted as necessary to exclude the effects of future reorganisations and asset enhancements. Discount factors are determined individually for each cash-generating unit and reflect management’s assessment of respective risk profiles, such as market and asset-specific risks factors. The assets are subsequently reassessed for indications that an impairment loss previously recognised may no longer exist. An impairment loss is reversed if the asset’s or cash-generating unit’s recoverable amount exceeds its carrying amount.
| 2.8 | Impairment of fixed assets and goodwill
Assets that are subject to depreciation or amortisation are assessed at each reporting date to determine whether there is any indication that the assets are impaired. Where there is any indication that an asset may be impaired, the carrying value of the asset (or cash-generating unit to which the asset has been allocated) is tested for impairment. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's (or CGU's) fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (CGUs). Non-financial assets that have been previously impaired are reviewed at each reporting date to assess whether there is any indication that the impairment losses recognised in prior periods may no longer exist or may have decreased.
| 2.9 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, inclusive of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.10 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.11 | Financial instruments
The Company recognises financial instruments when it becomes a party to the contractual arrangements of the instrument. Financial instruments are de-recognised when they are discharged or when the contractual terms expire. The Company's accounting policies in respect of financial instruments transactions are explained below: Financial assets and financial liabilities are initially measured at fair value. Page 14
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024 2.Accounting policies (continued)
| 2.11 | Financial instruments (continued)
Financial assets All recognised financial assets are subsequently measured in their entirety at either fair value or amortised cost, depending on the classification of the financial assets. Debt instruments at amortised cost Debt instruments are subsequently measured at amortised cost where they are financial assets held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and selling the financial assets, and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Amortised cost is calculated using the effective interest method and represents the amount measured at initial recognition less repayments of principal plus the cumulative amortisation using the effective interest method of any difference between the initial amount and the maturity amount, adjusted for any loss allowance. Impairment of financial assets The Company recognises a loss allowance for expected credit losses on investments in debt instruments that are measured at amortised or at FVOCI. The amount of expected credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument. The Company always recognises lifetime ECL for trade receivables and amounts due on contracts with customers. The expected credit losses on these financial assets are estimated based on the Company's historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate. Lifetime ECL represents the expected credit losses that will result from all possible default events over the expected life of a financial instrument. Financial liabilities At amortised cost Financial liabilities which are neither contingent consideration of an acquirer in a business combination, held for trading, nor designated as at fair value through profit or loss are subsequently measured at amortised cost using the effective interest method. This is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or where appropriate a shorter period, to the amortised cost of a financial liability.
| 2.12 | Creditors
Creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Creditors are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method. Page 15
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024 2.Accounting policies (continued)
| 2.13 | Foreign currency translation
Functional and presentation currency The Company's functional and presentational currency is GBP (£). Transactions and balances Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges. Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of comprehensive income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.
| 2.14 | Leases
Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: ∙Fixed payments (including in-substance fixed payments), less any lease incentives receivable: ∙Variable lease payments that are based on an index or a rate, initially measured using the index or rate as at the commencement date; ∙Amounts expected to be payable by the Company under residual value guarantees; ∙The exercise price of a purchase option if the Company is reasonably certain to exercise that option; and ∙Payments of penalties for terminating the lease, if the lease term reflects the Company exercising that option. Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability. The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Company, the lessee’s incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. Page 16
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024 2.Accounting policies (continued) 2.14 Leases (continued) Right-of-use assets are measured at cost comprising the following: ∙The amount of the initial measurement of lease liability; ∙Any lease payments made at or before the commencement date less any lease incentives received; ∙Any initial direct costs; and ∙Restoration costs. Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis.
| 2.15 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
| 2.16 | Dividends
Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.
| 2.17 | Pensions
Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.
| 2.18 | Interest income
Interest income is recognised in profit or loss using the effective interest method. Page 17
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024 2.Accounting policies (continued)
| 2.19 | Provisions for liabilities
Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation. Provisions are charged as an expense to profit or loss in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the reporting date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties. When payments are eventually made, they are charged to the provision carried in the Statement of financial position.
| 2.20 | Current and deferred taxation
The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income. Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that: ∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and ∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met. Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.
3. | Judgements in applying accounting policies and key sources of estimation uncertainty
Estimates and Assumptions The key estimates and assumptions concerning the future and other key sources of estimation uncertainty at the financial reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below: Page 18
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024 3.Judgements in applying accounting policies and key sources of estimation uncertainty (continued) Estimating useful lives of depreciable assets The annual depreciation charge depends primarily on the estimated lives of each type of asset and, in certain circumstances, estimates of fair values and residual values. The directors annually review these asset lives and adjust them as necessary to reflect current thinking on remaining lives in light of technological change, prospective economic utilisation and physical condition of the assets concerned. Changes in asset lives can have significant impact on depreciation charges for the period. It is not practical to quantity the impact of changes in asset lives on an overall basis, as asset lives are individually determined, and there are a significant number of asset lives in use. The impact of any change would vary significantly depending on the individual changes in assets and the classes of assets impacted. Provision for expected credit losses of trade receivables The Company measures expected credit losses of a financial instrument in a way that reflects an unbiased and probability-weighted amount that is determined by evaluating a range of possible outcomes, the time value of money and information about past events, current conditions and forecasts of future economic conditions. When measuring ECL, the Company uses reasonable and supportable forward-looking information, which is based on assumptions for the future movement of different economic drivers and how these drivers will affect each other.
4. | Turnover
| An analysis of turnover by class of business is as follows:
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Software and support sales | 4,822,623 | 4,709,386
| All turnover arose within the United Kingdom.
5. | Operating profit
| The operating profit is stated after charging:
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Depreciation of tangible fixed assets | 37,340 | 36,695
| Impairment of intangible assets | 257,317 | -
| Exchange differences | (8,369) | 6,997
| Defined contribution pension cost | 31,690 | 26,521
Page 19
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024
6. | Employees
| The average monthly number of employees, including the directors, during the year was as follows:
|  |  | 2024 | 2023
|  |  | No. | No.
|  | Sales and marketing staff | 4 | 3
|  | Customer service and training staff | 16 | 16
|  | Technology staff | 3 | 2
|  | Finance staff | 1 | 1
|  |  | 24 | 22
| The directors did not receive any remuneration during the year (2023: £Nil).
7. | Interest payable and similar expenses
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Lease interest payable | 1,768 | 4,131
8. | Taxation
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Corporation tax |  |
| Current tax on profits for the year | 128,000 | 81,884
| Adjustments in respect of previous periods | (14,667) | (922)
| Origination and reversal of timing differences | (30,446) | -
| Taxation on profit on ordinary activities | 82,887 | 80,962
Page 20
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024 8.Taxation (continued)
| Factors affecting tax charge for the year
| The tax assessed for the year is lower than (2023: lower than) the standard rate of corporation tax in the UK of 25% (2022: 23.5%). The differences are explained below:
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Profit on ordinary activities before tax | 1,570,217 | 1,446,293
| Profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 25% (2023: 23.5%) | 392,554 | 339,879
| Effects of: |  |
| Capital allowances for year in excess of depreciation | (9,693) | (37,188)
| Depreciation & amortisation | 65,913 | -
| Expenses not deductible for tax purpose | 1,564 | -
| Other timing differences | - | 13,638
| Other provision in prior years | (14,667) | (922)
| Group relief of losses | (322,338) | (234,445)
| Write-off of deferred tax liability | (30,446) | -
| Total tax charge for the year | 82,887 | 80,962
Page 21
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024
9. | Intangible assets
|  | Development expenditure
|  | £
| Cost |
| At 1 January 2024 | 222,336
| Additions - internal | 34,981
| At 31 December 2024 | 257,317
| Impairment |
| Impairment charge | 257,317
| At 31 December 2024 | 257,317
| Net book value |
| At 31 December 2024 | -
| At 31 December 2023 | 222,336
| The Company commenced a project in June 2022 to upgrade the back-end coding for the DGL SQL system, with associated costs capitalized as intangible assets. However, following a detailed review and assessmnet of the project's feasibility, it was determined that the upgrade was not viable due to excessive costs. As a result, the Company has written off the capitalized costs related to this project in the current financial year.
Page 22
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024
10. | Tangible fixed assets
|  | Fixtures and fittings | Right of use asset | Total
|  | £ | £ | £
| Cost or valuation |  |  |
| At 1 January 2024 | 23,199 | 155,064 | 178,263
| At 31 December 2024 | 23,199 | 155,064 | 178,263
| Depreciation |  |  |
| At 1 January 2024 | 6,375 | 121,466 | 127,841
| Charge for the year on owned assets | 6,333 | 31,008 | 37,341
| At 31 December 2024 | 12,708 | 152,474 | 165,182
| Net book value |  |  |
| At 31 December 2024 | 10,491 | 2,590 | 13,081
| At 31 December 2023 | 16,824 | 33,598 | 50,422
| The right-of-use asset relates to an office building with a remaining term of 1 month. There are no leases with extension options, options to purchase, variable payments linked to an index or with lease termination options.
11. | Debtors: Amounts falling due within one year
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Trade debtors | 336,992 | 465,015
| Amounts owed by group undertakings | 8,923,067 | 7,229,834
| Prepayments | 144,432 | 120,348
| Other debtors | 5,524 | 13,528
| Contract assets | 8,201 | 8,201
|  | 9,418,216 | 7,836,926
| All amounts are recoverable within one year. Amounts owed by group undertakings are unsecured and repayable on demand. Interest was charged between 4.7% and 5.2%.
Page 23
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024
12. | Cash and cash equivalents
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Bank and cash balances | 429,207 | 398,524
13. | Creditors: Amounts falling due within one year
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Trade creditors | 42,787 | 81,505
| Amounts owed to group undertakings | - | 288
| Corporation tax | 128,000 | 66,446
| Other taxation and social security | 249,720 | 280,864
| Lease liability | 3,028 | 33,948
| Other creditors | 6,344 | 5,551
| Accruals | 273,344 | 213,424
| Deferred income | 392,560 | 514,009
|  | 1,095,783 | 1,196,035
| Amounts owed to group undertakings are unsecured, repayable on demand. Glas Trust Corporation Limited hold a fixed and floating charge over the assets of the Company. Lease liabilities are secured by way of the underlying asset.
14. | Creditors: Amounts falling due after more than one year
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Lease liability | - | 4,336
| Glas Trust Corporation Limited hold a charge over the assets of the Company.
Page 24
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024
15. | Deferred taxation
|  | 2024
|  | £
| At beginning of year | 30,446
| Charged to profit or loss | (30,446)
| At end of year | -
| The deferred taxation balance is made up as follows:
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Accelerated capital allowances | - | (30,446)
16. | Share capital
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
|  | Allotted, called up and fully paid |  |
|  | 2 Ordinary shares of £1.00 each | 2 | 2
17. | Reserves
Other reserves Other reserves comprises of capital contributions to Clanwilliam Health (DGL) Limited. Profit and loss account Includes all current and prior period retained profits and losses.
18. | Pension commitments
The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £31,690 (2023: £26,521). Contributions totalling £6,344 (2023: £5,551) were payable to the fund at 31 December 2024. Page 25
Clanwilliam Health (DGL) Limited
Notes to the financial statements For the year ended 31 December 2024
19. | Commitments under leases
| At 31 December 2024 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Not later than 1 year | 3,028 | 33,948
| Later than 1 year and not later than 5 years | - | 4,336
|  | 3,028 | 38,284
20. | Controlling party
The immediate parent company is Clanwilliam Investments (U.K.) Limited, a company incorporated in the United Kingdom. The smallest and largest consolidated financial statements presented are that of Clanwilliam Headquarters Limited. They are publicly available from the Companies Registration Office, Bloom House, Gloucester Place Lower, Dublin 1. Clanwilliam Headquarters Limited is owned by a UK trust called The Clanwilliam Group Trust. M H Steven Wilson is the sole trustee and is the ultimate controlling party. On 21 February 2025, the shareholder of the Group agreed to sell 100% of the shares in the Company to Tribe Bidco Limited, a special purpose vehicle incorporated by TA Associates.
21. | Related party transactions
| The Company has availed of the exemption under Financial Reporting Standard 101 section 8(k) not to give details of related party transactions with fellow group companies as they are 100% controlled by a UK Investment Holding Trust.
22. | Post balance sheet events
On 21 February 2025, the shareholder of the Group agreed to sell 100% of the shares in the Company to Tribe Bidco Limited, a special purpose vehicle incorporated by TA Associates. There are no other subsequent events that will require adjustment or disclosure in the Company's financial statements.
Page 26